The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.
Overview
- Phase
- Phase 4
- Intervention
- Reconvan, Dipeptiven, Omegaven
- Conditions
- Gastrointestinal Surgery
- Sponsor
- Jagiellonian University
- Enrollment
- 600
- Locations
- 1
- Primary Endpoint
- Immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
The study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients following elective upper GI surgery
Detailed Description
All patients qualified between June 2002 and December 2007 to total and distal subtotal gastrectomy or pancreaticoduodenectomy were screened for eligibility to participate in the study. Malnutrition was defined by the Nutritional Risk Index (NRI), calculated according to the formula used in the Veterans Administration Cooperative Group trial.{, 1991 #70} Additional eligibility criteria included: age between 18 and 80 years, Karnofsky performance status score of 80 or more, and adequate organ function measured by routine blood tests. Patients without features of malnutrition, as well as those with disseminated tumors, serious comorbidities (American Society of Anesthesiologists risk class of 4 or 5), and renal or liver failure were excluded. The study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients following elective upper GI surgery. Therefore, patients were randomly assigned in a 2×2 factorial design to four groups receiving immunostimulating versus normal diets, and enteral versus intravenous nutritional support. The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and the length of hospital stay.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age between 18 and 80 years,
- •Karnofsky performance status score of 80 or more,
- •adequate organ function measured by routine blood tests
Exclusion Criteria
- •patients \<18 or \> 80
- •Karnofsky performance \< 50
Arms & Interventions
4
Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
Intervention: Reconvan, Dipeptiven, Omegaven
1
Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
Intervention: Reconvan, Dipeptiven, Omegaven
2
Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
Intervention: Reconvan, Dipeptiven, Omegaven
3
Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
Intervention: Reconvan, Dipeptiven, Omegaven
Outcomes
Primary Outcomes
Immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients
Time Frame: Immunonutrition
Secondary Outcomes
- To evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and the length of hospital stay(morbidity)